BUZZ-Tempest Therapeutics jumps on agreement with Roche to advance liver cancer drug study

Reuters10-10

** Shares of drug developer Tempest Therapeutics up 19.21% at $1.60 premarket

** TPST to conduct a late-stage study of its experimental drug amezalpat, in combination with Swiss drugmaker Roche's

Tecentriq and bevacizumab, for the treatment of metastatic hepatocellular carcinoma, a form of liver cancer

** Under the agreement, Roche will supply Tecentriq globally and Tempest will sponsor and lead the study

** Company to prepare for the start of the late-stage study in Q1 of 2025

** TPST retains all development and commercial rights to amezalpat

** As of last close, Tempest stock down 69.32% YTD

(Reporting by Bageshri Banerjee)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2474374580?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-10 21:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2474374580","market":"us","top_or_hot":-1,"title":"BUZZ-Tempest Therapeutics jumps on agreement with Roche to advance liver cancer drug study","media":"Reuters","content":"<html><body><p>** Shares of drug developer Tempest <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>    up 19.21% at $1.60 premarket</p><p>   ** TPST to conduct a late-stage study of its experimental drug amezalpat, in combination with Swiss drugmaker Roche's</p><p>  Tecentriq and bevacizumab, for the treatment of metastatic hepatocellular carcinoma, a form of liver cancer </p><p>   ** Under the agreement, Roche will supply Tecentriq globally and Tempest will sponsor and lead the study</p><p>   ** Company to prepare for the start of the late-stage study in Q1 of 2025</p><p>   ** TPST retains all development and commercial rights to amezalpat</p><p>   ** As of last close, Tempest stock down 69.32% YTD</p><p> (Reporting by Bageshri Banerjee)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Tempest Therapeutics jumps on agreement with Roche to advance liver cancer drug study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Tempest Therapeutics jumps on agreement with Roche to advance liver cancer drug study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-10 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>** Shares of drug developer Tempest Therapeutics    up 19.21% at $1.60 premarket   ** TPST to conduct a late-stage study of its experimental drug amezalpat, in combination with Swiss drugmaker Roche's...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2474374580","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2474374580","pubTimestamp":1728566222,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"** Shares of drug developer Tempest Therapeutics    up 19.21% at $1.60 premarket   ** TPST to conduct a late-stage study of its experimental drug amezalpat, in combination with Swiss drugmaker Roche's  Tecentriq and bevacizumab, for the treatment of metastatic hepatocellular carcinoma, a form of liver cancer    ** Under the agreement, Roche will supply Tecentriq globally and Tempest will sponsor and lead the study   ** Company to prepare for the start of the late-stage study in Q1 of 2025   ** TPST retains all development and commercial rights to amezalpat   ** As of last close, Tempest stock down 69.32% YTD ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","TPST":"Tempest Therapeutics Inc.","LENZ":"Therapeutics"},"translate_title":"BUZZ-Tempest Therapeutics与罗氏达成协议推进肝癌药物研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"TPST":0.9},"content_text":"** Shares of drug developer Tempest Therapeutics    up 19.21% at $1.60 premarket   ** TPST to conduct a late-stage study of its experimental drug amezalpat, in combination with Swiss drugmaker Roche's  Tecentriq and bevacizumab, for the treatment of metastatic hepatocellular carcinoma, a form of liver cancer    ** Under the agreement, Roche will supply Tecentriq globally and Tempest will sponsor and lead the study   ** Company to prepare for the start of the late-stage study in Q1 of 2025   ** TPST retains all development and commercial rights to amezalpat   ** As of last close, Tempest stock down 69.32% YTD (Reporting by Bageshri Banerjee)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2474374580"}